Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Completed(1)

Detailed Status

Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

active_not_recruiting150%
completed150%

Recent Activity

1 active trials
Showing 2 of 2
active_not_recruitingphase_1

Pausing Antiretroviral Treatment Under Structured Evaluation

NCT06031272
completedphase_1

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

NCT04173819

Clinical Trials (2)

Showing 2 of 2 trials
NCT06031272Phase 1

Pausing Antiretroviral Treatment Under Structured Evaluation

Active Not Recruiting
NCT04173819Phase 1

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

Completed

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2